Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2017 16:01 ET | Source: Apricus Biosciences

Apricus Biosciences Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals

Apricus Expects to Receive Approximately $12.7 Million from Ferring Apricus to Focus on Vitaros U.S. NDA Re-Submission and Pipeline Assets Post-ClosingSAN DIEGO, March 08, 2017 (GLOBE NEWSWIRE) --...
January 18, 2017 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Mexico

SAN DIEGO, Jan. 18, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
December 27, 2016 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences Announces the Launch of Vitaros® for the Treatment of Erectile Dysfunction in Lebanon by Elis Pharmaceuticals

SAN DIEGO, Dec. 27, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the...
October 26, 2016 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Greece

SAN DIEGO, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
September 21, 2016 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences Announces the Launch of Vitaros® in the Czech Republic and Slovakia by Recordati

SAN DIEGO, Sept. 21, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the...
September 08, 2016 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Argentina

SAN DIEGO, Sept. 08, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
September 06, 2016 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in Portugal, Ireland and Poland by Recordati

SAN DIEGO, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the...
July 25, 2016 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences Further Expands Existing Vitaros® Partnership with Ferring Pharmaceuticals in Europe and Asia

Apricus Eligible to Receive an Additional $3.6 Million in Upfront and Pre-Commercialization Milestone Payments for the Expanded Territory Apricus and Sandoz Agree to Mutually Terminate...
August 08, 2011 10:03 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences to File for Market Authorization to Sell Vitaros(R) for Erectile Dysfunction in Latin America

SAN DIEGO, Aug. 8, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it will file for market authorization to sell its erectile dysfunction drug,...